The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial
- DOI
- 10.1093/jnci/djag095
- Published
- 2026-04-03
- Container
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/jnci/djag095,
title = {The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial},
author = {Elisa Agostinetto and Gabriella Gentile and Faye Samy and Serena Di Cosimo and Philippe Aftimos and Noam Pondé and Daniel Eiger and Matteo Lambertini and David Cameron and Astrid Kiermaier and Andrew Bailey and Giuseppe Viale and Sherene Loi and Martine Piccart and Evandro de Azambuja},
year = {2026},
journal = {JNCI: Journal of the National Cancer Institute},
doi = {10.1093/jnci/djag095},
url = {https://doi.org/10.1093/jnci/djag095}
}RIS
TY - JOUR TI - The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial AU - Elisa Agostinetto AU - Gabriella Gentile AU - Faye Samy AU - Serena Di Cosimo AU - Philippe Aftimos AU - Noam Pondé AU - Daniel Eiger AU - Matteo Lambertini AU - David Cameron AU - Astrid Kiermaier AU - Andrew Bailey AU - Giuseppe Viale AU - Sherene Loi AU - Martine Piccart AU - Evandro de Azambuja PY - 2026 JO - JNCI: Journal of the National Cancer Institute DO - 10.1093/jnci/djag095 UR - https://doi.org/10.1093/jnci/djag095 ER -
APA
Agostinetto, E., Gentile, G., Samy, F., Cosimo, S. D., Aftimos, P., Pondé, N., Eiger, D., Lambertini, M., Cameron, D., Kiermaier, A., Bailey, A., Viale, G., Loi, S., Piccart, M., & Azambuja, E. D. (2026). The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag095
Source records
- crossref · retrieved 2026-09-26T16:45:09.065Z